Cover Image
Market Research Report
Product code
1032077

Lewy body disease - Pipeline Insight, 2021

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Lewy body disease - Pipeline Insight, 2021
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

DelveInsight's, "Lewy body disease - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Lewy body disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Lewy body disease Understanding

Lewy body disease: Overview

Lewy body disease is caused by the degeneration and death of nerve cells in the brain. The name comes from the presence of abnormal spherical structures, called Lewy bodies, which develop inside nerve cells. It is thought that these may contribute to the death of the brain cells. They are named after the doctor who first wrote about them. It is sometimes referred to as Diffuse Lewy body disease. At present there is no known cause of Lewy body disease, and no known risk factors have been identified. There is no evidence that it is an inherited disease. This type of dementia is diagnosed by taking a careful history of the pattern of symptoms, and by excluding other possible causes such as Vascular dementia and Alzheimer's disease. A brain scan may reveal brain degeneration, but the Lewy bodies can only be identified by examination of brain tissue after death. At present there is no cure for Lewy body disease. Symptoms such as depression and disturbing hallucinations can usually be reduced by medication. However, medications to relieve hallucinations may increase muscle tremors and stiffness. Conversely, anti-Parkinson drugs may make hallucinations worse.

"Lewy body disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lewy body disease pipeline landscape is provided which includes the disease overview and Lewy body disease treatment guidelines. The assessment part of the report embraces, in depth Lewy body disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lewy body disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Lewy body disease R&D. The therapies under development are focused on novel approaches to treat/improve Lewy body disease.

Lewy body disease Emerging Drugs Chapters

This segment of the Lewy body disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lewy body disease Emerging Drugs

Irsenontrine (E 2027): Eisai Inc

A selective phosphodiesterase (PDE) 9 inhibitor that reduces the degradation of cyclic GMP, which is critical to signal transmission among cells. Expected to be a new treatment for dementia with Lewy bodies and Parkinson's disease dementia by helping to maintain the concentration of cyclic GMP in the brain.

Neflamapimod: EIP Pharma

Neflamapimod is an investigational drug that is a brain-penetrant, oral small molecule that inhibits the intra-cellular enzyme p38 MAP kinase alpha (p38α). P38α, which is expressed in neurons under conditions of stress and disease, plays a major role in inflammation-induced synaptic toxicity, leading to impairment of synaptic function. Synaptic dysfunction is known to be a major drive of the cognitive and functional deficits function seen in many CNS diseases.

Mevidalen: Eli Lilly and Company

LY3154207 (Mevidalen formally called D1 PAM) is a chemical entity that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the treatment of symptomatic lewy body dementia. Currently, it is in Phase II stage of development.

Further product details are provided in the report……..

Lewy body disease: Therapeutic Assessment

This segment of the report provides insights about the different Lewy body disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lewy body disease

There are approx. 15+ key companies which are developing the therapies for Lewy body disease. The companies which have their Lewy body disease drug candidates in the most advanced stage, i.e. phase II include, Eli Lilly and Company.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Lewy body disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lewy body disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lewy body disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lewy body disease drugs.

Lewy body disease Report Insights

  • Lewy body disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Lewy body disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Lewy body disease drugs?
  • How many Lewy body disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lewy body disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lewy body disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lewy body disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Eisai Inc.
  • EIP Pharma
  • KeifeRx
  • Generian Pharmaceuticals, Inc.
  • Aptinyx
  • Eli Lilly and Company
  • Sun Pharma Advanced Research Company
  • CuraSen Therapeutics
  • NeuroActiva
  • Neurimmune Therapeutics
  • Voyager Therapeutics
  • Yumanity Therapeutics
  • Immungenetics
  • ProMIS Neurosciences
  • NLS Pharmaceutics Ltd
  • Inhibikase Therapeutics

Key Products

  • Irsenontrine (E 2027)
  • Neflamapimod
  • Nilotinib
  • Bosutinib
  • GT300
  • NYX-458
  • LY3154207
  • K0706
  • CST-103
  • NA-831
  • NI 004
  • Research programme: vectorised anti-alpha synuclein antibody therapeutics
  • YTX-9184
  • Research programme: ABC-transporter modulators
  • Research programme: neurodegenerative disease therapeutics
  • IkT 148x
Table of Contents
Product Code: DIPI1403

Table of Contents

Introduction

Executive Summary

Lewy body disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Lewy body disease - DelveInsight's Analytical Perspective

Mid Stage Products (Phase II)

  • Comparative Analysis

Mevidalen: Eli Lilly and Company

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

NI 004: Neurimmune Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

YTX 9184: Yumanity Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Lewy body disease Key Companies

Lewy body disease Key Products

Lewy body disease- Unmet Needs

Lewy body disease- Market Drivers and Barriers

Lewy body disease- Future Perspectives and Conclusion

Lewy body disease Analyst Views

Lewy body disease Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Lewy body disease
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Lewy body disease
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products